¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"rate limiting enzyme"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • exposure rate
    ³ëÃâ·ü, ÇÇÆø·ü
  • exposure rate constant
    ÇÇÆø·ü»ó¼ö
  • early neonatal mortality rate
    Á¶±â½Å»ý¾Æ»ç¸Á·ü
  • energy metabolic rate
    ¿¡³ÊÁö´ë»çÀ²
  • erythrocyte sedimentation rate
    ÀûÇ÷±¸Ä§°­¼Óµµ, Ç÷ħ¼Óµµ
  • fatality rate
    Ä¡¸í·ü
  • fertility rate
    »ý½Ä·ü
  • fetal death rate
    žƻç¸Á·ü
  • fetal heart rate
    žƽɹڼö
  • filtration rate
    ¿©°úºñ, ¿©°úÀ², ¿©°ú¼Óµµ
  • five-year survival rate
    ¿À³â»ýÁ¸À²
  • fixed rate pacemaker
    °íÁ¤¼Óµµ¹Úµ¿Á¶À²±â
  • flow rate
    1. À¯¼Ó 2. À¯·®
  • fractional fibrinogen catabolic rate
    ºÐȹº°¼¶À¯¼Ò¿ø´ë»çÀ²
  • frame rate
    È­¸é¹ß»ý·ü, È­¸éÀ²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • mortality rate curve
    »ç¸Á·ü°î¼±
  • rate constant
    ¼Óµµ»ó¼ö
  • death rate
    »ç¸Á·ü
  • defect rate
    °áÇÔ·ü
  • diffusion rate
    È®»êÀ²
  • disability rate
    Àå¾ÖÀ²
  • disappearance rate
    ¼Ò½Ç·ü
  • divorce rate
    ÀÌÈ¥À²
  • dose rate
    ¼±·®·ü
  • dose rate effect
    ¼±·®À²È¿°ú
  • dose rate meter
    ¼±·®À²°è, ¼±·®·üÃøÁ¤±â
  • dose rate variation
    ¼±·®·üº¯ÀÌ
  • early neonatal mortality rate
    ½Å»ý¾Æ»ç¸Á·ü
  • egg negative conversion rate
    Ãæ¶õÀ½ÀüÀ²
  • egg reduction rate
    Ãæ¶õ°¨¼ÒÀ²
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • flavin enzyme
    Ç÷¹À̺óÈ¿¼Ò.
  • glycine cleavage enzyme system
  • glycolytic enzyme
    ÇØ´çÈ¿¼Ò
  • glycolytic enzyme
    ÇØ´çÈ¿¼Ò.
  • heterogeneous enzyme immunoassay
    ºÒ±ÕÀÏ<--Áú>È¿¼Ò¸é¿ªÇÐÀûÃøÁ¤(¹ý)
  • homogeneous enzyme immunoassay
    ±ÕÁúÈ¿¼Ò¸é¿ªÃøÁ¤(¹ý)
  • induced enzyme
    À¯µµÈ¿¼Ò.
  • inducible enzyme
    À¯¹ß°¡´ÉÈ¿¼Ò
  • inducible enzyme
    À¯µµ(¹ß)È¿¼Ò.
  • inhibitory enzyme
    ÀúÇØÈ¿¼Ò.
  • inorganic enzyme
    ¹«±âÈ¿¼Ò(ÙíѦý£áÈ).
  • intracellular enzyme
    ¼¼Æ÷³»È¿¼Ò.
  • lipoclastic enzyme
    ÁöÁúºÐÇØÈ¿¼Ò.
  • lipolytic enzyme
    ÁöÁúºÐÇØÈ¿¼Ò.
  • lipolytic enzyme 192
    ÁöÁúºÐÇØÈ¿¼Ò 192
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • enzyme unit
    È¿¼Ò´ÜÀ§ (ý£áÈÓ¤êÈ)
  • enzyme variant
    È¿¼Ò º¯ÀÌü(ý£áÈܨì¶ô÷)
  • essential enzyme
    Çʼö È¿¼Ò (ù±âÎý£áÈ)
  • extracellular enzyme
    ¼¼Æ÷¿Ü È¿¼Ò(á¬øàèâý£áÈ)
  • fatty acid activating enzyme
    Áö¹æ»ê Ȱ¼ºÈ­ È¿¼Ò (ò·Û¸ß«üÀàõûùý£áÈ)
  • flavin enzyme
    Ç÷¹À̺ó È¿¼Ò(ý£áÈ)
  • glycine cleavage enzyme
    ±Û¶óÀ̽ŠºÐÇÒ È¿¼Ò(ÝÂùÜý£áÈ)
  • heat-sensitive enzyme
    ¿­¹Î°¨ È¿¼Ò(æðÚÂÊïý£áÈ)
  • heterotropic enzyme
    ÀÌÁú È¿¼Ò(ì¶òõý£áÈ)
  • homologous enzyme variants
    »óµ¿ È¿¼Ò º¯ÀÌü(ßÓÔÒý£áÈܨì¶ô÷)
  • homotropic enzyme
    µ¿Áú È¿¼Ò(ÔÒòõý£áÈ)
  • hydrolytic enzyme
    °¡¼öºÐÇØ È¿¼Ò(Ê¥â©ÝÂú°ý£áÈ)
  • immobilized enzyme
    °íÁ¤ È¿¼Ò(ͳïÒý£áÈ)
  • incision enzyme
    Àý°³ È¿¼Ò(ï·ËÒý£áÈ)
  • indicator enzyme
    Áö½ÃÈ¿¼Ò(ò¦ãÆý£áÈ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
UFR ultrafiltration rate; urine filtration rate
VCR vasoconstriction rate; vincristine; volume clearance rate
ACE Angiotensin Converting Enzyme
  = Kininase II
  = Dipeptidyl Carboxypepti...
EIA   1) Exercise Induced Asthma; ¿îµ¿ À¯¹ß¼º õ½Ä
  = EIB
  2) Enzyme Immu...
ELISA Enzyme-Linked Immuno-Sorbent Assay; È¿¼Ò ¸é¿ª¹ý
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
EMIT Enzyme Immunoassay
EIA Enzyme Immunosorbent Assay
ELISA Enzyme Linked Immunoassay
EITB Enzyme Linked Immunoelectro Transfer Blot
ELLA Enzyme Linked Lectin Assay
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
enzyme regulation <biochemistry> Control of the rate of a reaction catalyzed by an enzyme by some effector (e.g., inhibitors or activators) or by alteration of some condition (e.g., pH or ionic strength).
(05 Mar 2000)
enzyme replacement therapy A type of medical treatment for patients who lack an important enzyme, the missing enzyme is injected into the patient.
(09 Oct 1997)
enzyme repression The interference in synthesis of an enzyme due to the elevated level of an effector substance, usually a metabolite, whose presence would cause depression of the gene responsible for enzyme synthesis.
(12 Dec 1998)
enzymes, coenzymes, and enzyme inhibitors Proteins or RNA that act as biological catalysts, their cofactors, and inhibitors.
(12 Dec 1998)
enzyme stabilisation Reducing the chances that an enzyme will inactivate in vitro (see enzyme inactivation) by changing the environmental conditions (such as pH, temperature, concentration of salt, etc.) or by attaching organic groups to it or changing some of its amino acid subunits.
(09 Oct 1997)
enzyme stability The extent to which an enzyme retains its structural conformation or its activity when subjected to storage, isolation, and purification or various other physical or chemical manipulations, including proteolytic enzymes and heat.
(12 Dec 1998)
enzyme-substrate complex A noncovalent complex of two molecules; often referring to the enzyme-substrate complex in an enzyme-catalyzed reaction.
Compare: central complex, Michaelis complex.
Synonym: enzyme-substrate complex.
(05 Mar 2000)
extracellular enzyme <enzyme> An enzyme performing its functions outside a cell; e.g., the various digestive enzyme's.
Synonym: exoenzyme, lyoenzyme.
(05 Mar 2000)
yellow enzyme Any enzyme that possesses a flavin nucleotide as coenzyme; e.g., xanthine oxidase, succinate dehydrogenase.
Synonym: yellow enzyme.
(05 Mar 2000)
UDP-N-acetylglucosamine-lysosomal-enzyme-N-acetylglucosaminephosphotransferase <enzyme> Fibroblasts from patients with i-cell (mucolipidosis II) and pseudo-hurler polydystrophy (mucolipidosis III) are deficient in above enzyme; for n-acetylglucosamine transferred to dolichyl phosphate see EC 2.7.8.15
Registry number: EC 2.7.8.17
Synonym: udpgnac gp gnac phosphotransferase, udpgnac phosphotransferase, uridine 5'-diphosphate-n-acetylglucosamine glycoprotein n-acetylglucosaminylphosphotransferase, n-acetylglucosamine-1-phosphotransferase, n-agapt, udp-n-acetylglucosamine-lysosomal glycoprotein n-acetylglucosaminylphosphotransferase, udp-acetylglucosamine-glycoprotein n-acetylglucosamine-1-phosphotransferase
(26 Jun 1999)
UDP-N-acetylglucosamine:lysosomal enzyme N-acetylglucosaminyl-1-phosphotransferase <enzyme> An enzyme that participates in the posttranslational modification of a number of lysosomal proteins; a deficiency or defect in this enzyme results in two forms of mucolipidoses, I-cell disease, and pseudo-Hurler polydystrophy.
(05 Mar 2000)
Kornberg enzyme DNA polymerase I from Escherichia coli.
(05 Mar 2000)
1,4-alpha-glucan branching enzyme <enzyme> In glycogen or amylopectin synthesis, the enzyme that catalyses the transfer of a segment of a 1,4-alpha-glucan chain to a primary hydroxy group in a similar glucan chain.
Chemical name: 1,4-alpha-D-Glucan:1,4-alpha-D-glucan 6-alpha-D-(1,4-alpha-D-glucano)-transferase
Registry number: EC 2.4.1.18
(12 Dec 1998)
liver enzyme <biochemistry> Special proteins found in the cells of the liver that are responsible for catalysing specific metabolic reactions. They may become elevated in the bloodstream in conditions of hepatitis or liver cancer.
See: liver function tests.
(27 Sep 1997)
lysosomal enzyme <biochemistry> A range of degradative enzymes, most of which operate best at acid pH. The best known marker enzymes are acid phosphatase and glucuronidase, but many others are known.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á